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Cardiovascular calcification in patients with end-stage renal burden of cardiovascular disease is even greater in older
disease: A century-old phenomenon. The mortality risk from car- diabetic patients who now represent the main patient pop-
diovascular disease is increased in patients with end-stage renal ulation contributing to the increasing incidence of ESRDdisease (ESRD). This is due to both traditional and dialysis-
in the U.S. There are a number of traditional and dialysis-specific factors. Recently, a number of the dialysis-specific risk
specific cardiovascular risk factors that may contributefactors have been implicated in the pathogenesis of cardio-
vascular calcification. These include: hyperphosphatemia, high to this burden. Until recently, traditional risk factors
calcium-phosphate (Ca  P) product, elevated parathyroid such as left ventricular hypertrophy, hypertension, poor
hormone levels, duration of dialysis, and treatment with cal- glycemic control and dyslipidemia have been targetedcium-containing phosphate binders and vitamin D analogs. The
as the main causes of the accelerated atherosclerosis andrecent availability of electron beam computed tomography
increased mortality in dialysis patients. More recently,(EBCT) has triggered increased awareness of the occurrence
of cardiovascular calcification in ESRD patients. Given the de- a number of dialysis-specific pathogenetic factors also
velopment of transient hypercalcemia with calcium-containing have been implicated including hyperphosphatemia, high
binders, a link between calcium load from use of calcium-con- Ca  P product, elevated parathyroid hormone levels,taining phosphate binders and development coronary calcifica-
as well as treatment with calcium-containing phosphatetion has been proposed. However, a causal relationship be-
binders and vitamin D analogs [2].tween use of these agents and cardiovascular calcification has
not been established. Moreover, this phenomenon had been Coronary artery calcification is absent in normal ves-
recognized over a century ago, long before these phosphate sels but usually occurs when atherosclerosis is present.
binders became available. Although its pathogenesis is likely Occasionally it may be detected in early atheroscleroticto be multifactorial, available data strongly implicate elevated
lesions that develop in the second and third decades ofserum phosphorus as the primary culprit. Furthermore, the
life, but it occurs more frequently in advanced lesionsrisk of calcification may be aggravated by vitamin D therapy,
particularly in patients with severe secondary hyperparathy- and in older individuals [3]. Electron-beam computed
roidism. Therefore, achieving vigorous control of serum phos- tomography (EBCT) and spiral computed tomography
phorus, Ca  P product and parathyroid hormone level might
(CT) are highly sensitive techniques for detecting coro-decrease cardiovascular calcification and improve survival of
nary artery calcification and are being used with increas-patients on maintenance hemodialysis. Since calcium acetate
is the most cost-effective phosphate binder available, we rec- ing frequency for screening asymptomatic individuals at
ommend that it should remain the first line treatment of hyper- risk for developing coronary artery disease [3]. Cur-
phosphatemia in patients with ESRD. rently, there is intense interest in the use of these non-
invasive techniques for screening patients with ESRD
for the presence of occult coronary artery disease. In
The risk of morbidity and mortality in patients with non-uremic patients, the presence of coronary artery
end-stage renal disease (ESRD) is high. Cardiovascular calcification has been shown to predict coronary artery
disease is extremely common and accounts for at least events such as myocardial infarction [4]. There is no
50% of deaths among these patients [1]. Moreover, mor- doubt that the prevalence of coronary artery calcifica-
tality from cardiovascular disease 20- to 30-fold higher tion, as well as valvular and myocardial calcification is
than in age-, gender- and race-matched controls. The increased in patients with ESRD [5–8]. These abnormali-
ties are usually clinically silent but can be detected by
fluoroscopy, conventional computed tomography, spiralKey words: hyperphosphatemia, hypercalcemia, phosphate binder, cal-
CT or EBCT. Quantification of the calcium load in thecium phosphate product, calcium acetate, Sevelamer, hydrochloride,
vitamin D, parathyroid hormone, EBCT, osteoblast. coronary arteries by EBCT is thought to reflect the total
atherosclerotic plaque burden. Therefore, the use of 2002 by the International Society of Nephrology
S-73
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EBCT offers the potential to evaluate the progression, sclerosis and is characterized by diffuse calcification of
the media, particularly at the level of the internal elasticstabilization, and even regression of calcification through
serial imaging. Despite the promise of EBCT as a screen- lamina. This form of calcification is commonly seen in
the coronary arteries of older individuals, particularlying test for coronary artery calcification, the technique
has not been standardized with regard to tomographic older diabetic patients with ESRD. A subgroup of pa-
tients with ESRD may develop a specific form of medialslice thickness. Furthermore, the reproducibility of the
calcium scoring system remains to be established [3, 4]. calcification known as calciphylaxis or uremic arteriolo-
pathy. In this type, calcification affects cutaneous andWhile the advent of these newer noninvasive screening
tests has increased awareness in the nephrology commu- subcutaneous arteries and arterioles, leading to occlusive
intimal proliferation. The resulting tissue ischemia leadsnity of the importance of soft tissue and vascular calcifi-
cation in dialysis patients, interest in this phenomenon to painful ulcers on the trunk and extremities and is
associated with extremely high mortality.is not new. In 1855, Virchow reported five cases of “meta-
static calcification” and renal disease was present in three
of them [9]. In his comprehensive review of this subject
PATHOGENESIS OF
in 1947, Mulligan found 27 autopsy cases of chronic renal
VASCULAR CALCIFICATION
disease with metastatic calcification; 15 had vascular cal-
Calcification normally occurs only in bones and teeth.cification involving the aorta, coronary arteries, as well as
Any calcification outside these organs including bloodthe renal, mesenteric, hepatic and peripheral arteries [10].
vessels is considered abnormal. Little is known about theFurthermore, 11 of these patients had myocardial and
actual mechanisms causing vascular and other tissue calci-valvular calcification. Calcium deposits were found both
fication. In healthy individuals, abnormal calcification doesin the intima and media of these arteries. In the early
not occur because of a delicate balance between factors1970s, the incidence of metastatic calcification in dialysis
promoting extraosseous calcification and other factorspatients was reported to vary between 38 and 81% [11, 12].
that inhibit calcification [2]. The presence of abnormalArterial calcification was even reported among patients
calcification implies a disturbance in this balance.with chronic renal failure who were not yet on dialysis.
In a series of elegant studies, Alfrey and Ibels concludedIn 1976, Meema, Oreopoulos and deVeber reported that
that pyrophosphate, an inhibitor of calcium phosphatearterial calcification developed in 38% of patients with
precipitation in normal urine, plays and important role increatinine clearance less than 20 mL/min who had not
abnormal calcification in uremia [15]. Pyrophosphate isbeen previously dialyzed, 43% in those beginning dialysis,
normally excreted in the urine but is retained in presenceand 44% among dialysis patients [13]. Repeated radiologic
of renal failure. Moreover, high serum phosphorus accel-studies showed that arterial calcification progressed in
erates pyrophosphate production. Elevated serum levels36% and 10% of their non-dialyzed and dialyzed pa-
of pyrophosphate have been reported in uremic patientstients, respectively. They speculated that progression of
[16, 17] and bone pyrophosphate is significantly higherarterial calcification was not due to dialysis per se, but
in dialyzed patients compared to control subjects [18]. Into prolongation of life in the presence of chronic renal
vitro, pyrophosphate is rapidly adsorbed from the incuba-failure. In an autopsy study of 56 dialyzed and 18 non-
tion medium onto the surface of apatite crystals [19]. Pyro-dialyzed patients with chronic renal failure, Kuzela and
phosphate is thought to inhibit the transformation of brush-colleagues found calcification in 79% of dialyzed patients
ite (amorphous calcium-phosphate) to hydroxyapatiteand 44% in the non-dialyzed patients [14]. Calcification
(normal bone mineral). These observations are consistentwas severe in 35% of patients and involved the cardiac
with the finding that the amount of apatite is reduced andmuscle, conduction system, coronary arteries as well as
the amount of amorphous calcium-phosphate (brushite)visceral organs including the lung, stomach and kidneys.
is increased in the bones of uremic animals [16]. It has
been proposed that accumulation of pyrophosphate in
CLINICAL AND PATHOLOGICAL FORMS OF bone may inhibit normal bone mineralization, and para-
EXTRAOSSEOUS CALCIFICATION doxically promote calcium and phosphorus deposition
in extraosseous tissues [15]. It is intriguing that in dialysisThere are three types of extraosseous calcification:
calcification in medium-sized arteries, periarticular calci- patients an inverse correlation between coronary artery
calcification and bone density has been reported [5].fication, and visceral calcification (heart, lung, and kid-
ney). Vascular calcification follows two distinct patho- Moreover, arterial calcification is increased in osteopo-
rotic women and animals with reduced bone mass [20, 21].logic patterns [2]. Intimal calcification, which occurs in
association with atherosclerotic plaques, is usually a focal It is likely that any pathogenetic process that interferes
with bone mineralization, including secondary hyperpara-process as adjacent areas of the vessel are not involved.
Medial calcification of arteries, the so-called Moncke- thyroidism, adynamic bone disease, and osteoporosis,
may predispose to vascular and soft tissue calcification.berg’s sclerosis, may be found in the absence of athero-
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The key question is what happens to the calcium and blasts are derived from a common bone marrow mesen-
chymal stem cell. Both pericytes and smooth muscle cellsphosphorus that are not deposited into bone in uremic
patients? Intuitively, one might think that the calcium retain their pluripotent character and therefore have the
ability to differentiate into osteoblasts [31]. The osteo-and phosphate simply deposit passively in other tissues
including blood vessels. Early observations that tissue blast produces most of the proteins present in bone extra-
cellular matrix (ECM) and it controls the mineralizationnecrosis is often followed by passive precipitation of
calcium-phosphate lead to the traditional view that vas- of this ECM. It is now clearly established that some
VSMCs can adopt a calcifying phenotype in vitro andcular calcification is a degenerative process that occurs
in association with atherosclerosis and normal aging. become the so-called calcifying vascular cells. Interest-
ingly, these cells have been shown to resemble osteoblastsHowever, it is remarkable that, almost 150 years ago,
Virchow believed that vascular calcification is indeed an and express the same sequence of bone-related proteins
(osteopontin, alkaline phosphatase and osteocalcin) ex-active process when he noted that, “Vascular calcification
is an ossification, and not a mere calcification. We see pressed by osteoblasts in normal mineralizing bone [32].
Osteocalcin, a protein required for mineralization ofossification declares itself in precisely the same manner
as when an osteophyte forms on the surface of bone” [22]. ECM, is the only gene expressed in osteoblasts but in no
other ECM-producing cell type [33]. Thus, osteocalcinIn the last decade, the widely accepted notion that extra-
osseous calcification is a passive phenomenon has once expression by calcifying vascular cells indicates that they
have acquired an osteoblastic phenotype. Moreover,again been seriously challenged, based on strong evi-
dence from experimental and genetic studies suggesting these calcifying vascular cells also express the transcrip-
tion factor cbfa1/osf2, which is absolutely essential forthat vascular calcification is an active and highly regu-
lated process similar to bone formation. In this regard, differentiation of mature osteoblasts in bone [34].
ectopic bone elements, which may even contain bone
marrow, have been described in calcified blood vessels,
ROLE OF CALCIUM IN
advanced atherosclerotic lesions, and in calcified cardiac VASCULAR CALCIFICATION
valves [23, 24]. These findings suggest that vascular cells
Intuitively, calcium, phosphorus and the calcium-phos-have the capacity to transform into osteoblast-like cells
phorus product (Ca P) should control the precipitationcapable of producing ectopic bone in the vessel wall
of calcium phosphate at all sites of mineralization, whether[25, 26]. These cells, now called calcifying vascular cells,
in bone, teeth, blood vessels, heart valves or periarticularhave been shown to resemble osteoblasts in that they
tissues. However, it is not entirely clear whether theseexpress bone matrix and morphogenic proteins thought
factors, either alone or in combination are primarily re-to be involved in regulating normal osteogenesis includ-
sponsible for vascular calcification in uremic patients.ing osteopontin, osteonectin, matrix GLA protein, osteo-
The potential role of calcium loading resulting fromcalcin, bone sialoprotein, and bone morphogenic protein
the use of calcium-containing phosphate binders has re-2a [27]. In particular, expression of osteocalcin, which is
cently become an area of major controversy. In a smallpathognomonic of osteoblastic terminal differentiation,
observational study, Goodman and colleagues reportedstrongly suggests that vascular cells assumed an osteo-
the presence of coronary calcification in 14 of 16 youngblastic phenotype.
adult hemodialysis patients between 20 and 30 years oldOur understanding of the relevance of these proteins
[6]. They found that patients with coronary calcificationin vascular calcification has been enhanced by the devel-
were older, had been on hemodialysis for a longer periodopment of knockout models. Mice lacking matrix GLA
of time, had higher mean serum phosphorus levels andprotein or osteoprotegerin develop medial calcification
Ca  P products as well as a greater prescribed dailyof arteries [28, 29]. These proteins are expressed in vascu-
dose of calcium-containing phosphorus binders. A sec-lar smooth muscle cells where they act as natural inhibi-
ond small observational study showed that carotid arterytors of vascular calcification. Furthermore, mice lacking
compliance and vascular calcification in patients withSmad6, an inhibitory molecule in the transforming growth
ESRD were positively correlated with the prescribedfactor- (TGF-) signaling pathway, have been shown
daily dose of calcium carbonate [7]. A multicenter trialto develop ectopic bone formation in the media of the
using EBCT is currently underway that is designed tooutflow tracts of the heart [30].
evaluate progression of coronary artery calcification in
dialysis patients treated with calcium-containing binders
ROLE OF VASCULAR SMOOTH MUSCLE CELLS compared to patients taking sevelamer hydrochloride [8].
Implicit in these reports is the concept that vascularThe origin of the calcifying vascular cells is not clearly
established, but they could be derived from microvascu- calcification is a passive degenerative process whereby
excess calcium simply deposits in extraosseous tissueslar pericytes or vascular smooth muscle cells (VSMCs)
[2]. Pericytes, along with smooth muscle cells and osteo- including blood vessels. This simplistic view ignores the
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vast body of evidence outlined earlier that clearly indi- concentration of 2.5 mEq/L leads to no net calcium flux
during dialysis [37]. Since there is no net calcium transfercates that vascular calcification is an active, highly regu-
lated process. In this regard, several lines of evidence with the use of low calcium dialysis, and given the im-
paired intestinal calcium absorption in uremia, onestrongly argue against a primary role for calcium loading
per se in the pathogenesis of vascular calcification. would predict that withdrawal of calcium-containing
binders might lead to negative calcium balance. Thus, itIt should be noted that cardiac calcification in dialysis
patients was reported decades before calcium-containing is not entirely unexpected that over 50% of patients
treated with the non-calcium phosphate binder sevelamerphosphate binders came into widespread use [14]. Fur-
thermore, most clinical studies have failed to demon- hydrochloride and 2.5 mEq/L dialysate calcium develop
hypocalcemia [38]. Accordingly, in order to avoid hypo-strate a significant correlation between the serum cal-
cium level and mortality risk in dialysis patients [5, 35, calcemia, it has been recommended that patients treated
with sevelamer hydrochloride receive supplementation36]. In one of the first observational cohort studies on
cardiovascular calcification, Braun and colleagues re- with nearly 1 gram of elemental calcium per day [39].
Interestingly, this calcium dose is almost equivalent toported an increased incidence of coronary artery, mitral,
and aortic valve calcification in hemodialysis patients the amount of elemental calcium contained in the aver-
age dose of calcium acetate required for control of hyper-compared to non-uremic patients with suspected or doc-
umented coronary artery disease [5]. They found that phosphatemia in the Calcium Acetate Renagel Evalua-
tion (CARE) Study as well as other studies [38, 40].age and hypertension independently correlated with the
total coronary calcification score. However, no correla- In sevelamer-treated patients, the supplemental dose of
calcium carbonate is usually given at night on an emptytion was found with serum calcium levels. Interestingly,
there was an inverse correlation between calcification stomach. Under such conditions, as much as 40% of the
administered dose of calcium may be absorbed [41]. Inscore and bone mass. This observation is in accord with
the hypothesis that impaired bone mineralization may contrast, about 15 to 20% of the elemental calcium is
be a prerequisite for the development of cardiovascular absorbed when calcium acetate is taken with meals [42].
calcification [21]. The paradox is that patients taking sevelamer along with
The association between coronary artery calcification supplemental calcium carbonate are likely to absorb just
and binder dose in the above-mentioned observational as much calcium as patients receiving calcium acetate
studies has been employed as the sole basis for targeting with meals as a phosphate binder.
calcium-containing binders as the primary cause of in-
creased cardiovascular calcification in dialysis patients.
ROLE OF PHOSPHORUS INWe believe that the paucity of scientific evidence does
VASCULAR CALCIFICATIONnot justify this conclusion. Results from observational
Hyperphosphatemia is universally present in patientsstudies should lead to hypothesis testing but cannot be
with ESRD and plays a key role in the development ofused to establish causation. Moreover, the exclusive em-
secondary hyperparathyroidism, extraosseous calcifica-phasis on the potential role of calcium loading in vascular
tion and calciphylaxis. Moreover, Block and colleaguescalcification totally ignores the pathogenic role of other
reported that patients with serum phosphorus levels ex-important factors such as the adequacy of phosphorus
ceeding 6.5 mg/dL have a 27% increased mortality riskcontrol, vitamin D usage, and parathyroid hormone. Al-
as compared to those with levels between 2.5 and 6.5though we cannot exclude a possible role for calcium
mg/dL [35]. Similarly, they found that patients with CaPloading, we believe that vascular calcification is not sim-
product exceeding 72 mg2/dL2 have a 34% increased riskply the result of intestinal absorption of excess calcium
of death as compared to those with products between 42from calcium-containing binders. Furthermore, the ac-
and 52 mg2/dL2. Since they found no correlation betweentual calcium load resulting from ingestion of calcium-
mortality risk and serum calcium levels, these authorscontaining phosphate binders may have been exagger-
concluded that the risk associated with increased Ca  Pated. In the absence of vitamin D therapy, intestinal
product was driven primarily by phosphorus. Levin andcalcium absorption is significantly decreased in patients
colleagues reported that the increased risk of death waswith ESRD, even when large doses of calcium-containing
primarily due to cardiac disorders, in particularly coro-binders are ingested. Most of this calcium becomes bound
nary artery disease (abstract; Levin et al, J Am Socto dietary phosphate and both are excreted in the stool.
Nephrol 9:217A, 1998). Similarly, Ganesh et al reportedMoreover, reduced levels of 1,25-dihydroxy vitamin D
a strong relationship between phosphorus level, Ca  Pfurther impair intestinal calcium absorption. Another
product, parathyroid hormone (PTH) level and cardio-potential source of calcium loading is the dialysate cal-
vascular causes of death, including sudden death [36].cium. However, while the use of a dialysate calcium
They proposed that serum phosphorus levels exceedingconcentration of 3.5 mEq/L results in a net positive cal-
cium flux, the currently recommended dialysate calcium 6.5 mg/dL may be a major cardiotoxin for hemodialysis
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Table 1. Dialysis patients with and without aortic andpatients, and may play a critical role in the development,
mitral valve calcification
progression, or rupture of atheromatous coronary artery
Valvular No valvularplaques.
calcification calcificationContrary to the lack of evidence against calcium load- Risk factors N  30 N  80
ing, there are a number of observations that link serum
Age years 647a 478
phosphorus levels with vascular calcification. Vascular % with Diabetes 55%a 25%
Duration of dialysis years 124a 73calcification was clearly documented in predialysis pa-
Serum calcium mg/dL 11.32a 9.43tients with chronic renal failure decades before the intro- Serum phosphorus mg/dL 6.92a 5.31
duction of calcium-containing phosphate binders [13, 14]. Ca  P product mg 2/dL2 789 497
PTH level pg/mL 73560 47583In that era, hyperphosphatemia also was thought to be
% with Vitamin D use 90% 10%the major risk factor for vascular calcification [15].
aP  0.01The molecular mechanisms regulating vascular calci-
fication remain unknown. In an in vitro model, high phos-
phorus levels in the incubation medium directly enhanced
extracellular calcification in human aortic smooth muscle ROLE OF VITAMIN D
cells via a sodium-dependent phosphate transporter-sen-
Administration of vitamin D to ESRD patients withsitive mechanism [43]. Moreover, high phosphorus levels
hyperparathyroidism is common practice. Unfortunately,increased the expression of the osteoblast-specific genes
vitamin D substantially increases the intestinal absorp-Osf2, Cbfa, and osteocalcin. These effects were mediated
tion of calcium and phosphorus, and therefore it mayby up-regulation of the sodium-phosphate cotransporter
increase the Ca P product and predispose to extraosse-Pit-1. In the KLOTHO-gene mutant mouse, a twofold
ous calcification. Furthermore, vitamin D has other ef-increase in serum phosphorus level led to an increased
fects that may predispose to vascular calcification. Ratscalcium-phosphate product and extensive vascular calci-
treated with high-dose vitamin D developed calcificationfication despite normal renal function [44].
in the aorta, and the carotid, hepatic, mesenteric, renalThese clinical and experimental observations strongly
and femoral arteries [49]. In other animal studies, priorargue for a primary role for elevated serum phosphorus
sensitization with parathyroid hormone or vitamin Din the development of vascular calcification in patients
resulted in calcification when the animals were subse-with chronic renal failure. It is likely that more vigorous
quently exposed to nonspecific stimuli including traumacontrol of serum phosphorus, Ca  P product and PTH
[50]. Mallick and Berlyne reported an association be-might lead to improved survival of patients on mainte-
tween vascular calcification and use of vitamin D therapynance hemodialysis [35, 36]. Consequently, Block and Port
in hyperphosphatemic patients with renal failure [51].recently recommended new goals for serum phosphorus
Vascular smooth muscle cells have been shown to ex-level (2.5 to 5.5 mg/dL) and Ca  P product (55 mg2/
press vitamin D receptors [52]. Although vitamin D in-dL2) [45]. Although dietary restriction of phosphate is
hibits VSMC proliferation by enhancing calcium fluxan important first step in effective phosphorus control,
into cells, it induces VSMCs to exhibit an osteoblasticwhen used alone it is often inadequate since phosphorus
phenotype [2]. Vitamin D also has been shown to in-is present in almost all food products, particularly those
crease calcification in VSMCs in vitro [52–54]. Moreover,with high protein content [46]. Furthermore, thrice weekly
vitamin D3 has been shown to increase the expressionhemodialysis alone is not particularly effective in controll-
of alkaline phosphatase in VSMCs [25]. In a study bying serum phosphorus because most of the total body phos-
one of us, echocardiography in dialysis patients identifiedphorus is located in the intracellular compartment [47].
30 patients with valvular calcification and 80 patientsConsequently, phosphate binders are routinely prescribed
without calcification [55]. Several factors were found toto patients with end-stage renal disease in order to mini-
be more common in patients with aortic and mitral valvemize the intestinal absorption of dietary phosphate. In
calcification than in those without calcification, includ-the last three decades, several phosphate binders have
ing: older age, diabetes, years on dialysis, hypercalcemia,been introduced into clinical practice. Although highly
hyperphosphatemia, high Ca  P product, and highereffective, aluminum-containing binders are no longer
PTH level (Table 1). Of interest, 90% of patients withroutinely prescribed because of the toxicities associated
valvular calcification were receiving vitamin D treatmentwith aluminum accumulation [48]. Calcium-containing
compared to only 10% of patients without calcification.binders such as calcium carbonate and calcium acetate,
Thus, both clinical and experimental studies suggest thatand most recently, the non-aluminum, non-calcium,
treatment of dialysis patients with vitamin D could be aphosphate binder sevelamer hydrochloride now has be-
major contributing factor to the increased risk of cardio-come the mainstay of treatment for hyperphosphatemia
in dialysis patients. vascular calcification.
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Table 2. Proposed dialysis-specific risk factors for cardiovascularROLE OF PARATHYROID HORMONE
calcification in uremic patients
Parathyroid hormone levels have been shown to corre-
Hyperphosphatemiaa serum phosphorus 5.5 mg/dLlate with increased risk of death in dialysis patients. Elevated Ca  P producta 55 mg2/dL2
Ganesh and colleagues found that a PTH level exceeding Exogenous vitamin D therapya
Elevated parathyroid hormone levels 500 pg/mL495 pg/mL was independently associated with sudden
Treatment with warfarindeath among their hemodialysis patients [36]. PTH en- Hypercalcemia
hances the release of calcium and phosphorus from bone Chronic inflammation elevated C-reactive protein
Elevated leptin levelsand may increase cytosolic calcium [20].
a Strong clinical and/or experimental evidence for importance as a risk factorIn addition, PTH-related peptide (PTHrP) has been
shown to stimulate VSMCs and osteoblast proliferation,
and promote the synthesis of the extracellular matrix
required for subsequent calcification [2]. There is a high
of calciphylaxis [62]. Thus, it is possible that the use ofdegree of sequence homology between PTHrP and PTH,
warfarin to maintain vascular access patency may pro-and they bind the PTH1R receptor with equal affinity.
mote the development of vascular calcification.Many studies have implicated PTH as a permissive factor
for cardiac fibroblast activation and myocardial fibrosis
[56]. Moreover, animal models have shown regression FUTURE CONSIDERATIONS
of myocardial fibrosis after parathyroidectomy [56]. Al- From the preceding discussion, it is clear that the issue
though available data do not establish causation, it is of vascular calcification in patients with renal failure is
possible that PTH itself is a cardiotoxin and that mark- more complicated than previously recognized. Although
edly elevated PTH levels could increase mortality risk its pathogenesis is likely to be multifactorial (Table 2), we
by inducing cardiovascular calcification. believe that currently available data strongly implicate
elevated serum phosphorus as the main culprit in vascu-
lar calcification. Therefore, vigorous control of serumROLE OF OTHER FACTORS IN
VASCULAR CALCIFICATION phosphorus must remain our primary treatment objec-
tive. In the U.S., the two most commonly prescribedThe role of inflammatory cytokines in vascular calcifi-
phosphate binders are calcium acetate and sevelamercation has not been carefully studied. Wang and col-
hydrochloride. Previous studies comparing these phos-leagues reported an increased risk of valvular calci-
phate binders suggested that they are equally effectivefication in peritoneal dialysis patients with elevated
in controlling serum phosphorus [63–66]. Unfortunately,C-reactive protein (CRP) and fibrinogen levels, both
these studies used open-label or single arm titration de-markers of inflammation [57]. Furthermore, there was a
signs. Moreover, in most of these studies, sevelamer hy-strong association between the degree of hypoalbumi-
drochloride was not usually effective in controlling serumnemia and valvular calcification [57]. Chronic renal fail-
phosphorus to the recommended goal of 5.5 mg/dL orure is associated with an increase in serum levels of
less [63, 65, 66]. The recently completed CARE study,leptin, which is a satiety factor that regulates food intake
a randomized double-blind trial, demonstrated that cal-and energy expenditure [58]. Leptin has been shown to
cium acetate is significantly more effective than seve-regulate osteoblastic differentiation and calcification of
lamer hydrochloride in controlling serum phosphorus toVSMCs, which are known to express leptin receptors
the goal level [38]. Calcium acetate-treated patients also[59]. These observations may explain the association be-
had a consistently lower Ca  P product compared totween malnutrition and increased cardiovascular calcifi-
sevelamer hydrochloride-treated patients. Thus, it is con-cation in dialysis patients.
ceivable that calcium acetate might reduce the risk ofThe role of advanced glycation end-products (AGE)
vascular calcification and mortality in dialysis patientsin vascular calcification was investigated by Yamagishi
as a result of better control of both serum phosphorusand colleagues, who reported that AGE significantly in-
and Ca  P product despite somewhat higher, albeitcreased the number of calcified nodules in cultured bo-
usually normal, serum calcium levels.vine pericytes [60]. They also showed that AGE in-
Despite the documented efficacy of calcium acetatecreased the pericyte expression of alkaline phosphatase
in treatment of hyperphosphatemia, some investigatorsand osteopontin mRNAs, markers of osteoblast differen-
have raised concerns about the potential risk of hypercal-tiation.
cemia and cardiovascular calcification with calcium-con-Finally, warfarin may play a role in vascular calcifica-
taining binders [6–8]. Since calcium acetate is twice astion. The target for warfarin is matrix Gla protein (MGP),
effective as calcium carbonate in binding dietary phos-a vitamin K-dependent protein secreted by VSMCs that
phate and contains half the amount of elemental calciuminhibits vascular calcification [61]. Interestingly, warfarin
also has been shown to be a risk factor for development [67], these two drugs should not be used interchangeably
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and phosphorus metabolism during maintenance hemodialysis.in phosphate binder studies, particularly when evaluating
Correlation of clinical, roentgenographic, and biochemical changes.
the incidence and long-term consequences of hypercalce- Am J Med 51:319–330, 1971
12. Conger JD, Hammond WS, Alfrey AC, et al: Pulmonary calcifica-mia. Although transient hypercalcemia occurs in dialysis
tion in chronic dialysis patients. Clinical and pathologic studies.patients treated with calcium-containing phosphate bind-
Ann Intern Med 83:330–336, 1975
ers, the results of the CARE study demonstrate that in 13. Meema HE, Oreopoulos DG, deVeber GA: Arterial calcifications
in severe chronic renal disease and their relationship to dialysiscalcium acetate-treated patients, hypercalcemia occurs
treatment, renal transplant, and parathyroidectomy. Radiologyexclusively in patients receiving concomitant vitamin D
121:315–321, 1976
therapy [38]. We therefore believe that hypercalcemia 14. Kuzela DC, Huffer WE, Conger JD, et al: Soft tissue calcification
in chronic dialysis patients. Am J Pathol 86:403–424, 1977can be avoided in the vast majority of calcium acetate-
15. Alfrey AC, Ibels LS: Role of phosphate and pyrophosphate intreated patients with the use of low calcium dialysate
soft tissue calcification. Adv Exp Med Biol 103:187–193, 1978
(2.5 mEq/L) and judicious use of vitamin D. Since the 16. Russell JE, Avioli LV: Effect of experimental chronic renal insuf-
ficiency on bone mineral and collagen maturation. J Clin Investissue of vascular calcification is critical to the very sur-
51:3072–3079, 1972vival of our patients, it must be more carefully evaluated
17. David DS, Sakai S, Granda J, et al: Role of pyrophosphate in
before we accept the overly simplistic notion that vascu- renal osteodystrophy. Trans Am Soc Artif Intern Organs 19:440–
445, 1973lar calcification is primarily caused by excess calcium
18. Alfrey AC, Solomons CC, Circillo J, Miller N: Bone pyrophos-intake in the form of calcium-containing phosphate bind-
phate in uremia and its association with extraosseous calcification.
ers. Furthermore, the potential role of vitamin D in vas- J Clin Invest 57:700–705, 1976
19. Alfrey AC, Solomons CC, Ciricillo J, Miller N: Extraosseouscular calcification has largely been ignored and demands
calcification. Evidence for abnormal pyrophosphate metabolismmore carefully scrutiny. In our view, the important issue
in uremia. J Clin Invest 57:692–699, 1976
of risk factors for cardiovascular calcification in dialysis 20. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium phos-
phate product and bone-associated proteins on vascular calcifica-patients can only be addressed by well-designed, double-
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